Diamyd Initiates European Submission for Phase III Diabetes Vaccine
Posted on: Monday, 21 January 2008, 09:01 CST
Diamyd Medical has initiated the application submission procedure, to start the European Phase III studies with the therapeutic diabetes vaccine Diamyd.
A submission has already been sent to the Swedish Medicinal Products Agency. Additional submissions will be sent to other European countries. The study is proposed to include approximately 300 patients at 30-50 European clinical sites in 3-5 countries.
Elisabeth Lindner, CEO of Diamyd Medical, said: "We are looking forward, through the coming national applications, to the gradual inclusion of more European countries and diabetes clinics in the European Phase III Study."
Source: Datamonitor
Related Articles
- Celanese Names Univar As Distributor for Mowilith(R) and Vinamul(R) Emulsions; New Relationship Positions Distributor to Provide Leading-Edge Polymer Emulsion Technology in Western European Countries
- Key European Countries Consider Offering Iran a Light-Water Nuclear Reactor
- NeoRx Expands Picoplatin Lung Cancer Clinical Trial Into Selected Eastern European Countries
- The Use of Photovoltaic is Set to Be a Major Source of Electricity for European Countries in the Coming Years
- Bird Flu Likely to Spread to More European Countries: OIE
- MediGene's Prostate Cancer Drug* Launched in France and Other European Countries
- An Analysis of CATV in the Major European Countries Including: the Major Players of Each Country, and an Overview of the Services Provided
- Research and Markets : Photovoltaic a Major Source of Electricity for the European Countries in the Coming Years, Read This and Other Predictions Up to 2010
- Research and Markets: Market for Molecular Biology Products Is Contracting in Major European Countries
- Obesity Higher in Some European Countries
Rating: 2.8 / 5 (6 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds